Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Chronic Obstructive Pulmonary Disease (COPD) is characterized by a persistent blockage of airflow in the lungs, which results in abnormal sputum, more than a “smoker’s cough” or a chronic cough and breathlessness. Symptoms of COPD include, cough, breathlessness (shortness of breath) and wheezing, sputum, chest infections, weight loss, tiredness, and ankle swelling.
The global asthma and COPD market is estimated to account for US$ 30,710.2 Mn in terms of value in 2020 and is expected to reach US$ 42,608 Mn by the end of 2027.
Global Asthma and COPD Market: Drivers
Increasing prevalence of COPD is expected to propel growth of the global asthma and COPD market over the forecast period. For instance, according to a report by Global Initiative for Chronic Obstruction Disease’s 2018 report, COPD is expected to result in 4.5 million global deaths annually by 2030.
Moreover, increasing member of smokers is also expected to aid in growth of the market. For instance, according to the World Health Organization, 1.337 billion people smoked tobacco worldwide in 2018.
Combination Therapies held dominant position in the global asthma and COPD market in 2019, accounting for 57.0% share in terms of value, followed by Bronchodilators and Anti-Inflammatories, respectively.
Figure 1. Global Asthma and COPD Market Share (%), by Value, by Drug Type, 2019
Global Asthma and COPD Market: Restraints
High cost of asthma treatment is expected to hinder growth of the market. For instance, the annual per-person medical cost of asthma is around US$ 4,000 in the U.S.
Moreover, asthma treatment is a long process and patients affected with the disease have to follow many precautions. Very often patients discontinue the treatment halfway because of high cost. This is also expected to limit the market growth.
Asthma and COPD Market Report Coverage
||Market Size in 2019:
||US$ 29,386.8 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 42,608.1 Mn
- North America: U.S., Canada
- Latin America: Brazil, Argentina, Mexico, Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
- Middle East: GCC Countries, Israel, Rest of Middle East
- Africa: South Africa, North Africa, Central Africa
- By Drug Type:
- Bronchodilators: Short Acting Bronchodilators, Long Acting Bronchodilators, Anticholinergics.
- Anti-Inflammatories: Inhaled Corticosteroids, Anti-Leukotriene, Monoclonal Antibodies.
- Combination Therapies
- By Disease Type: Asthma, COPD.
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Drug Stores.
AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Merck & Co., Verona Pharma plc,, Regeneron Pharmaceuticals, Inc., and Boehringer Ingelheim GmbH
- High prevalence of respiratory diseases
- Product launches
|Restraints & Challenges:
The global asthma and COPD market was valued at US$ 29,386.8 Mn in 2019 and is forecast to reach a value of US$ 42,608.1 Mn by 2027 at a CAGR of 4.8% between 2020 and 2027.
Figure 2. Global Asthma and COPD Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027
Market Trends/Key Takeaways
Major organizations are focused on offering guidelines regarding management of asthma during the Covid-19 pandemic. For instance, in July 2020, Asthma and Allergy Foundation of America released a comprehensive guide, the “COVID-19 and Asthma Toolkit for Schools” to help educators and families of children living with asthma navigate best methods to stay healthy for those returning to classrooms during the COVID-19 pandemic.
R&D of novel therapies is expected to propel growth of the global asthma and COPD market. For instance, the study, ‘Masitinib Significantly Decreases the Rate of Asthma Exacerbations in Patients with Severe Asthma Uncontrolled by Oral Corticosteroids: A Phase 3 Multicenter Study’, reported in June 2020, stated that Masitinib significantly reduced asthma exacerbations in patients with severe asthma uncontrolled by oral corticosteroids compared with placebo treatment.
Global Asthma and COPD Market: Competitive Landscape
Major players operating in the global asthma and COPD market include, AstraZeneca, Novartis AG, GlaxoSmithKline plc, Merck & Co., Verona Pharma plc,, Regeneron Pharmaceuticals, Inc., GlaxoSmithKline plc, and Boehringer Ingelheim GmbH.
Global Asthma and COPD Market: Key Developments
Major players in the market are focused on R&D of new therapies to expand their product portfolio. For instance, in July 2020, AstraZeneca's results from the positive Phase III ETHOS trial were published in the New England Journal of Medicine. The study demonstrated that the triple-combination therapy PT010 (budesonide/glycopyrronium/formoterol fumarate) reduced the rate of moderate or severe exacerbations compared with two dual-combination therapies in patients with moderate to very severe COPD.
Major players in the market are also focused on approval and launch of new products to expand their product portfolio. For instance, in February 2020, European Medicines Agency accepted GlaxoSmithKline plc’s regulatory submission seeking an additional indication for the use of once-daily, single-inhaler triple therapy, Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI) for the treatment of asthma in adults.